
NASDAQHealthcareMedical - Devices
最新データ
$65.74
+$1.52 · +2.37%
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
前日終値
$65.74
+$1.52 · +2.37%
日中の時刻はETです。市場データは遅延する場合があります。
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
日中レンジ
現在 $65.74
52週レンジ
現在 $65.74
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
84
大幅な割安
センチメント
63
強気
リスク
34
中程度のリスク
モメンタム
34
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
日中レンジ
現在 $65.74
52週レンジ
現在 $65.74
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 206.25億 USD | 196.72億 USD | 195.52億 USD | 183.41億 USD | 175.85億 USD |
| 売上原価 | 123.78億 USD | 114.67億 USD | 116.3億 USD | 111.62億 USD | 104.11億 USD |
| 粗利益 | 82.47億 USD | 82.05億 USD | 79.22億 USD | 71.79億 USD | 71.74億 USD |
| 研究開発 | 12.6億 USD | 13.11億 USD | 12.05億 USD | 10.26億 USD | 8.16億 USD |
| 販売・一般管理 | 42.25億 USD | 42.69億 USD | 42.82億 USD | 36.31億 USD | 35.63億 USD |
| 営業費用 | 54.85億 USD | 55.8億 USD | 54.87億 USD | 46.57億 USD | 43.79億 USD |
| 受取利息 | — | — | 2600万 USD | — | 3400万 USD |
| 支払利息 | 4.5億 USD | 5.05億 USD | 5.42億 USD | 8600万 USD | 4000万 USD |
| 減価償却費と償却費 | 5.78億 USD | 5.8億 USD | 6.1億 USD | 6.33億 USD | 6.25億 USD |
| 営業利益 | 27.62億 USD | 26.25億 USD | 24.35億 USD | 25.22億 USD | 27.95億 USD |
| 純利益 | 20.84億 USD | 19.93億 USD | 15.68億 USD | 19.16億 USD | 22.47億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
分割調整後の1株当たりの年間現金分配金。
$0.14
2025年(通年)+16.7% 以来 2024
2026年(一部):$0.105
$0.12
2,024
$0.14
2,025
$0.105
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当予定 | 2026年10月23日 | $0.04Quarterly | 2026年10月23日 | 2026年11月13日 |
配当 | 2026年7月24日 | $0.035Quarterly | 2026年7月24日 | 2026年8月14日 |
配当 | 2026年4月2日 | $0.035Quarterly | 2026年4月3日 | 2026年5月15日 |
配当 | 2026年1月9日 | $0.035Quarterly | 2026年1月9日 | 2026年2月13日 |
配当 | 2025年10月24日 | $0.035Quarterly | 2025年10月24日 | 2025年11月14日 |
配当 | 2025年7月25日 | $0.035Quarterly | 2025年7月25日 | 2025年8月15日 |
配当落ち 2026年10月23日
$0.04
Quarterly
2026年10月23日基準 · 支払日 2026年11月13日
配当落ち 2026年7月24日
$0.035
Quarterly
2026年7月24日基準 · 支払日 2026年8月14日
配当落ち 2026年4月2日
$0.035
Quarterly
2026年4月3日基準 · 支払日 2026年5月15日
配当落ち 2026年1月9日
$0.035
Quarterly
2026年1月9日基準 · 支払日 2026年2月13日
配当落ち 2025年10月24日
$0.035
Quarterly
2025年10月24日基準 · 支払日 2025年11月14日
配当落ち 2025年7月25日
$0.035
Quarterly
2025年7月25日基準 · 支払日 2025年8月15日
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。